The NeurologyLive® Parkinson disease Disease Spotlight page gives readers key updates and detailed coverage on the most recent expert conversations and data presentations relevant to the treatment of the movement disorder.
August 29th 2024
Phase 1b trials involving patients with Parkinson are planned for late 2024, with data expected by mid-2025.
Cognitive and Functional Differences Identified in Parkinson Disease Prior to Diagnosis
March 13th 2023Findings showed that global cognition declines in the prediagnostic period in men but not women with incident Parkinson disease, further indicating cognitive heterogeneity in the prodromal period by sex.
The Future of Genetic Approaches, New Targets in Parkinson Disease: James Beck, PhD
March 9th 2023The senior vice president and chief scientific officer of the Parkinson’s Foundation discussed the potential for new therapies that target genetically mutated forms of Parkinson disease. [WATCH TIME: 3 minutes]
Reasons for the Increase in Parkinson Disease Incidence: James Beck, PhD
March 6th 2023The senior vice president and chief scientific officer of the Parkinson’s Foundation detailed some of the potential reasons for the nearly 50% increase from the previously estimated rate. [WATCH TIME: 5 minutes]
Sex, Geographic Differences in the Incidence of Parkinson Disease: James Beck, PhD
February 21st 2023The senior vice president and chief scientific officer of the Parkinson’s Foundation provided perspective on recently published findings showing a nearly doubling of Parkinson disease incidence that previously reported. [WATCH TIME: 4 minutes]
Greater Burden of Care Identified in Caregivers of Patients With Advanced Parkinson Disease
February 11th 2023Caregivers of patients with advancing PD were more likely to spend more hours caring per day and had a higher self-perceived burden, compared with caregivers for patients with early PD.
Inspiring and Educating Young Medical Professionals to Parkinson Disease Care: Eli Pollard
February 10th 2023The chief training and education officer at the Parkinson’s Foundation discussed the inclusion of various medical professionals that assist in Parkinson disease care, and the need to provide access to educational tools to inform clinicians. [WATCH TIME: 5 minutes]
Cognitive Impairments in Activities of Daily Living Predict Conversion to Parkinson Disease Dementia
January 26th 2023After a follow-up of nearly 4 years, nearly half of the patients (n = 10) with baseline classification of cognitive IADL impairment and mild cognitive impairment converted to dementia.
Mesdopetam Fails to Improve ON Time But Shows Anti-Dyskinesia Effects in Parkinson Disease
January 25th 2023Mesdopetam showed significant effects on the secondary end point of Unified Dyskinesia Rating Scale, an assessment of involuntary movements associated with long-term treatment with dopaminergic medication.
Research Identifies Protective Drugs Toward Parkinson Disease, Warranting Future Consideration
January 16th 2023Plain sulfonamide diuretics was identified as a drug chemical subgroup potentially inversely associated with Parkinson disease risk, while weaker signals included insulin and ß2-adrenergic agonists.
Pimavanserin Lowers Mortality Better in Parkinson Disease Than Other Atypical Antipsychotics
January 6th 2023Findings from a large-scale trial of adults aged 65 and older with Parkinson disease showed that treatment with pimavanserin was associated with lower risk of mortality than other atypical antipsychotics.
Range of Risk Factors, Comorbidities, and Prodromal Features Identified Prior to Parkinson Disease
December 9th 2022Subsequent diagnosis of Parkinson disease was associated with a range of risk factors such as alcohol misuse and traumatic head injury, along with several other comorbidities and prodromal features.